Orexo (STO:ORX) touted results today from a 20-person pharmacokinetic study of its OX124-001 naloxone nasal spray. The company’s product is designed to reverse opioid overdoses. In the PK study, Orexo compared its drug to Narcan – the market-leading naloxone rescue medication. Sweden-based Orexo reported that all formulations of OX124 were well-tolerated by study participants and showed […]
Vital Therapies pulls the trigger on Immunic share swap
Vital Therapies (NSDQ:VTL) said today that it inked a deal to swap shares with Germany-based Immunic, transitioning its efforts to focus on Immunic’s pipeline of drugs for chronic inflammatory and autoimmune diseases. Once the deal is closed, Vital Therapies plans to operate under the name Immunic and trade on the Nasdaq market. A group of investors, […]
Bigfoot Biomedical inks insulin deal with Eli Lilly
Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory […]
Dexcom Q4 prelims top consensus | Wall Street Beat
Dexcom (NSDQ:DXCM) topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results. The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year. For the full year of 2018, Dexcom is slated […]
Frequency Therapeutics raises $42m for hearing regeneration drug
Frequency Therapeutics said today that it closed a $42 million Series B round to support the clinical development of its hearing regeneration drug, FX-322. The company is slated to publish top-line data from an ongoing Phase I/II study of FX-322 in the first half of the year. The Series B round was led by Taiwania […]
Pops! Diabetes Care raises funds for newly-approved glucose monitoring system
Pops! Diabetes Care said yesterday that it closed a new equity financing round to support the launch of its newly-approved Pops! One blood glucose monitoring system. The Park Heights, Minn.-based company did not disclose how much money it raised but it did report that 30Ventures led the round. “We are honored by the support and […]
Senseonics touts first U.S. trial implant of 180-day CGM
Senseonics (NYSE:SENS) said yesterday that its Eversense XL 180-day continuous glucose sensor was implanted into the first participant of a trial designed to support a pre-market application to the FDA. The company’s 180-patient Promise trial is slated to study the safety and efficacy of the Eversense device in people with diabetes over 180 days. Senseonics also […]
Medtronic, IBM Watson debut hypoglycemia prediction feature for diabetes app
Medtronic (NYSE:MDT) and IBM Watson Health today launched a new feature for its Sugar.IQ personal diabetes assistant app that can predict the likelihood of a user experiencing a low glucose event within a four-hour window. The feature, called IQcast, uses AI tech from IBM and becomes more accurate as the low blood sugar event draws nearer, […]
Results RNA recalls eye drops over undeclared colloidal silver
Results RNA said this week that it voluntarily recalled its Lubrisine eye drops following an FDA inspection that found the product was not manufactured with sterile practices. The company also said that the eye drops, which are designed to lubricate dry eyes, were found to contain undeclared colloidal silver. Exposure to colloidal silver over an […]
Valeritas’ V-Go wins preferred status on Humana’s Medicare formularies
Valeritas (NSDQ:VLRX) said today that its V-Go insulin delivery device won preferred status on Humana’s Part D formularies. The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. Worn like a patch, the V-Go product delivers a continuous preset basal rate of insulin over 24 hours and can also provide on-demand bolus dosing […]
